Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02KAU
|
|||
| Former ID |
DCL001220
|
|||
| Drug Name |
PF-03882845
|
|||
| Synonyms |
UNII-34ZKU73FU3; 34ZKU73FU3; CHEMBL1215331; 1023650-66-9; PF-3882845; (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; compound 2 [PMID: 24738581]; SCHEMBL552307; GTPL9061; DTXSID70144940; XNULRSOGWPFPBL-REWPJTCUSA-N; (+/-)-(3SR,3aRS)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; BDBM50324210; ZINC58583489; DB11814; NCGC00485023-01; PF-03882845, >
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Terminated | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22ClN3O2
|
|||
| Canonical SMILES |
C1CCC(C1)C2C3CCC4=C(C3=NN2C5=CC(=C(C=C5)C#N)Cl)C=CC(=C4)C(=O)O
|
|||
| InChI |
1S/C24H22ClN3O2/c25-21-12-18(8-5-17(21)13-26)28-23(14-3-1-2-4-14)20-10-6-15-11-16(24(29)30)7-9-19(15)22(20)27-28/h5,7-9,11-12,14,20,23H,1-4,6,10H2,(H,29,30)/t20-,23-/m0/s1
|
|||
| InChIKey |
XNULRSOGWPFPBL-REWPJTCUSA-N
|
|||
| CAS Number |
CAS 1023650-66-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mineralocorticoid receptor (MR) | Target Info | Modulator | [2] |
| KEGG Pathway | Aldosterone-regulated sodium reabsorption | |||
| Pathwhiz Pathway | Kidney Function | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Pfizer (2011). | |||
| REF 2 | Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.J Med Chem.2010 Aug 26;53(16):5979-6002. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.